An interventional study of Panel Effective Photobiomodulation Therapy and Sham Panel Photobiomodulation Therapy in Hypertension, sponsored by Universidade Federal de Sao Carlos. Recruiting at 1 site in Brazil. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-11-08.
Sponsored by Universidade Federal de Sao Carlos · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.
Among the 209 studies in Hypertension with a site in Brazil, this one is the 128th largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2024, is one of 112 with no phase, reaches primary completion later than 1 of the 32 other live ones, and was the 185th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:
University of Nove de Julho · Sites in Brazil
Ages 18–65
AstraZeneca · Sites in Brazil
Ages 18+
Instituto Dante Pazzanese de Cardiologia · Sites in Brazil
Ages 18+
Raphael Mendes Ritti Dias · Sites in Brazil
Ages 60+
Universidade Federal Fluminense · Sites in Brazil
Ages 18–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 40 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 40 · Phase 4 31
First in 1999; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 80 across the 189 interventional studies, 127 across the 18 observational. Of the 136 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 209 have an industry lead sponsor. The 10 most frequent:
Universidade Federal de Sao Carlos is the lead sponsor of 86 studies on the registry; 8 are open to participants now.
Universidade Federal de Sao Carlos has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypertension with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07361276AstraZenecaObservational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System | 2026-11-30 |
| NCT06105775University of Sao PauloInorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies | 2026-12 |
| NCT06169241National Institute of Cardiology, Laranjeiras, BrazilEffect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients | 2026-12 |
| NCT06917131Universidade Federal FluminenseRoyal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension | 2026-12-10 |
Add all 18 to your calendar (.ics) → With an account.
Among the 209 studies in Hypertension with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind and sham-controlled clinical trial that aims to evaluate and compare the acute effect of full-body photobiomodulation (PBM) and modified ILIB (Intravascular laser irradiation of blood) on blood pressure, endothelial function and arterial stiffness in individuals with hypertension. Participants (n=48) will be equally, randomly and secretly allocated into one of 4 groups: Panel Group; Panel Sham Group; Modified ILIB group; and Modified ILIB Sham Group. Participants aged 40 to 60 years old, diagnosed with hypertension and using control drugs for at least 3 months will be included. Participants will be assessed at pre- and post-intervention for: BP; endothelial function; arterial stiffness; blood nitrite; and thermography. In the post-intervention period, the ambulatory blood pressure monitoring will also be carried out. Participants will receive a single application of PBM, which, depending on the group, may be full-body irradiation from an LED panel (660 nm; 25.34 J/cm²; 42.24 mW/cm²), modified ILIB (660 nm; 42,462 J/cm²; 35.385 W/cm²), or the respective sham therapies. Data homogeneity and normality will be verified by the Levene and Shapiro-Wilk tests, which will determine the choice of subsequent tests. A statistical significance of 5% will be considered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who will receive full-body photobiomodulation irradiation, from a panel of LEDs
Device: Panel Effective Photobiomodulation Therapy
Participants who will receive full-body photobiomodulation irradiation, with the device turned-off
Device: Sham Panel Photobiomodulation Therapy
Participants who will receive photobiomodulation irradiation with the transcutaneous ILIB method
Device: Modified ILIB Photobiomodulation Therapy
Participants who will received photobiomodulation irradiation with the transcutaneous ILIB method, with the device turned-off
Device: Modified ILIB Sham Photobiomodulation Therapy
Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals. This group will receive photobiomodulation from a whole-body panel of low intensity LEDs
Use of common red lamp to perform the sham photobiomodulation for the panel group
ILIB Therapy device turned off for the sham ILIB therapy
Common laser used in ILIB mode for modified ILIB therapy
Diastolic Blood Pressure
Diastolic blood pressure measured in millimeters of mercury (mmHg)
Time frame: Acute effect (immediately post-intervention until 24 hours after)
Systolic Blood Pressure
systolic blood pressure measured in millimeters of mercury (mmHg)
Time frame: Acute effect (immediately post-intervention until 24 hours after)
Mean Arterial Pressure
mean arterial pressure measured in millimeters of mercury (mmHg)
Time frame: Acute effect (immediately post-intervention until 24 hours after)
Endothelial Function
Endothelial function measured by flow-mediated dilation, with a brachial artery ultrasound
Time frame: Acute effect (About 25 minutes post-intervention)
Arterial Stiffness
Arterial stiffness measured by pulse wave velocity
Time frame: Acute effect (About 15 minutes post-intervention)
Blood Nitrite
Blood nitrite levels
Time frame: Acute effect (1 hour post-intervention)
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Jan 2025, 8 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidade Federal de Sao Carlos